Ironwood Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$460.1Mnext fiscal year
FY EPS (est.)
$1.09next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 29 Oct 2026 |
| Q4 2026 Earnings Release | 18 Feb 2027 |
Monitoring Framework
Key Performance Indicators
LINZESS U.S. Net Sales Quarterly272.5MTarget: $1.125 billion to $1.175 billion
Ironwood Total Revenue Quarterly106.5MTarget: $450 million to $475 million
Adjusted EBITDA Quarterly76.7MTarget: Greater than $300 million
Watch Items
- STARS-2 Phase III Confirmatory Trial Site InitiationTrigger: Initiation of clinical sites for apraglutide in short bowel syndrome with intestinal failure (SBS-IF)Action: Monitor progress updates on patient enrollment and site activation during the Q2 and Q3 2026 earnings calls.
- Interim and Permanent CFO AppointmentTrigger: Transition following the resignation of CFO Gregory Martini effective May 15, 2026Action: Track the announcement of an interim and permanent CFO to resolve leadership uncertainty.
- Repayment of 1.50% Convertible Senior NotesTrigger: Maturity of convertible notes on June 15, 2026Action: Verify cash settlement of the notes using the company's Q1 cash balance and Q2 operating cash flows.
Research as of 19 Jun 2026